-
Electronic (PDF)
-
Site License
-
Enterprisewide
Curacyte AG - Product Pipeline Review - 2012
Global Markets Direct, July 2012, Pages: 33
Curacyte AG – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Curacyte AG - Product Pipeline Review - 2012” provides data on the Curacyte AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Curacyte AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Curacyte AG and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Curacyte AG - Brief Curacyte AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Curacyte AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Curacyte AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Curacyte AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Curacyte AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Curacyte AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Curacyte AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Curacyte AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Curacyte AG and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Curacyte AG; Curacyte AG - Key Therapeutics; Curacyte AG - Pipeline Overview and Promising Molecules; Curacyte AG - News; Curacyte AG - Latest Updates; Curacyte AG - Pipeline; Curacyte AG - Discontinued/Dormant Projects
2
List of Tables 4
List of Figures 4
Curacyte AG Snapshot 5
Curacyte AG Overview 5
Key Information 5
Key Facts 5
Curacyte AG – Research and Development Overview 6
Key Therapeutic Areas 6
Curacyte AG – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Curacyte AG – Pipeline Products Glance 10
Curacyte AG Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Curacyte AG – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Curacyte AG – Drug Profiles 13
CD 160130 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Hemoximer 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Plasmin And Plasma Kallikrein Inhibitor 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Protease Inhibitors 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Curacyte AG – Pipeline Analysis 18
Curacyte AG – Pipeline Products by Therapeutic Class 18
Curacyte AG – Pipeline Products By Target 19
Curacyte AG – Pipeline Products by Route of Administration 20
Curacyte AG – Pipeline Products By Mechanism of Action 21
Curacyte AG – Recent Pipeline Updates 22
Curacyte AG - Discontinued Pipeline Products 23
Discontinued Pipeline Product Profiles 23
Hemoximer 23
Curacyte AG – Locations And Subsidiaries 24
Head Office 24
Financial Deals Landscape 25
Curacyte AG, Deals Summary 25
Curacyte AG, Pharmaceuticals & Healthcare, Deal Details 26
Venture Financing 26
Curacyte Raises $37.8 Million In Series C Financing 26
Merger 28
Curacyte Merges With IBFB PHARMA 28
Asset Transactions 29
Fraunhofer Institute Acquires Technology Platform From Curacyte 29
Acquisition 30
The Medicines Acquires Curacyte Discovery From Curacyte 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Curacyte AG, Key Information 5
Curacyte AG, Key Facts 5
Curacyte AG – Pipeline by Indication, 2012 7
Curacyte AG – Pipeline by Stage of Development, 2012 8
Curacyte AG – Monotherapy Products in Pipeline, 2012 9
Curacyte AG – Phase II, 2012 10
Curacyte AG – Pre-Clinical, 2012 11
Curacyte AG – Discovery, 2012 12
Curacyte AG – Pipeline By Therapeutic Class, 2012 18
Curacyte AG - Pipeline By Target, 2012 19
Curacyte AG – Pipeline By Route of Administration, 2012 20
Curacyte AG – Pipeline Products By Mechanism of Action, 2012 21
Curacyte AG – Recent Pipeline Updates, 2012 22
Curacyte AG - Discontinued Pipeline Products, 2012 23
Curacyte AG, Deals Summary 25
Curacyte Raises $37.8 Million In Series C Financing 26
Curacyte Merges With IBFB PHARMA 28
Fraunhofer Institute Acquires Technology Platform From Curacyte 29
The Medicines Acquires Curacyte Discovery From Curacyte 30
List of Figures
Curacyte AG – Pipeline by Indication, 2012 7
Curacyte AG – Pipeline by Stage of Development, 2012 8
Curacyte AG – Monotherapy Products in Pipeline, 2012 9
Curacyte AG – Pipeline By Therapeutic Class, 2012 18
Curacyte AG – Pipeline By Route of Administration, 2012 20
Curacyte AG - Pipeline Products By Mechanism of Action, 2012 21
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
